By Bhanvi Satija LONDON, April 29 (Reuters) - Strong first-quarter results under new GSK CEO Luke Miels on Wednesday failed to impress investors, who raised concerns that the British drugmaker's ...

The company also said General Medicines, particularly Trelegy, performed better than expected. Along with a favorable product mix, GSK claimed it benefitted in the quarter from a successful Zejula ...

YUPELRI® Collaboration Revenue increased 15% year-over-year1, from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage ...

Earnings call GSK delivered a strong Q1 2026 with sales up 5% YoY to over GBP 7.6 billion, driven by Specialty Medicines (+14%) and record Shingrix sales (+20%). Core operating profit rose 10%, EPS ...

Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%Net cash provided by operating activities of $718 millionRaised ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

GlaxoSmithKline’s latest earnings call struck an upbeat tone, with management emphasizing broad‑based momentum in specialty medicines, vaccines and late‑stage R&D, even as legacy general medicines and ...

Trelegy Ellipta is a maintenance treatment for patients with asthma and COPD. "The FDA's acceptance of our ANDA filing for ...

GSK has finally called time on its pact with Mersana Therapeutics despite sinking $100 million to secure an option for an antibody-drug conjugate (ADC). That deal, signed back in 2022, centered on XMT ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

GSK (GSK) reported better-than-expected financials for Q1 2026 on Wednesday as sales from its HIV and cancer medicines offset a sales decline for its general medicines, including its respiratory ...